In leukemia and neuroblastoma models, IL-12-expressing CAR-iNKT cells demonstrate superior anti-tumor efficacy compared to IL-15-expressing counterparts by promoting Th1 polarization and molecular reprogramming that enhances activation and proliferation while limiting exhaustion and generating long-lived memory iNKT cells (89). The gene discussed is IL15; the disease is neoplasm.